Vectibix
Biological
Amgen Inc.
Total Payments
$43.1M
Transactions
5,465
Doctors
1,776
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $111,788 | 64 | 36 |
| 2023 | $14.6M | 180 | 133 |
| 2022 | $725,459 | 161 | 141 |
| 2021 | $5.9M | 81 | 55 |
| 2020 | $5.5M | 1,416 | 767 |
| 2019 | $7.6M | 1,034 | 291 |
| 2018 | $4.7M | 1,016 | 303 |
| 2017 | $3.9M | 1,513 | 390 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $40.8M | 174 | 94.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 952 | 3.9% |
| Travel and Lodging | $348,411 | 1,108 | 0.8% |
| Consulting Fee | $182,190 | 67 | 0.4% |
| Food and Beverage | $133,036 | 3,107 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $34,904 | 55 | 0.1% |
| Education | $66.18 | 2 | 0.0% |
Payments by Type
Research
$40.8M
174 transactions
General
$2.4M
5,291 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AMG 510 Ph1b Master Protocol 20190135 | Amgen Inc. | $13.2M | 0 |
| Phase II trial of panitumumab, nivolumab and ipilimumab for KRAS/NRAS/BRAF wild-type MSS refractory metastatic colorectal adenocarcinoma | Amgen Inc. | $7.8M | 0 |
| A Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer Patients | Amgen Inc. | $4.7M | 0 |
| PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy after Progression on Anti-EGFR Therapy in Patients with Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | Amgen Inc. | $3.3M | 0 |
| Women's Triple Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients with Localized Triple-Negative Breast Cancer (TNBC) with Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy | Amgen Inc. | $2.3M | 0 |
| A Randomized Phase II Study of Hepatic Arterial Infusion with FUDR and Dexamethasone and Intravenous Irinotecan, 5FU and Leucovorin with or without Panitumumab, in Patients with Wild Type KRAS who have Resected Hepatic Metastases from Colorectal Canc | Amgen Inc. | $2.0M | 0 |
| A randomized phase II study of neoadjuvant carboplatin/paclitaxel (CT) versus panitumumab/carboplatin/paclitaxel (PaCT) followed by anthracycline-containing regimen for newly diagnosed primary triple negative inflammatory breast cancer | Amgen Inc. | $1.6M | 0 |
| Phase II pilot study of FOLFOXIRI plus panitumumab in metastatic RAS wild type, leftsided colorectal cancer | Amgen Inc. | $1.5M | 0 |
| Randomized Phase III Trial of 5-FU Based Maintenance Therapy with or without Panitumumab in Patients with RAS WT Metastatic Colorectal Cancer after Induction with FOLFOX+Panitumumab | Amgen Inc. | $768,009 | 0 |
| Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients with Localized Triple-Negative Breast Cancer (TNBC) with Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy | Amgen Inc. | $758,640 | 0 |
| P3 3L + Vectibix vs Pi choice CRC CB 300 | Amgen Inc. | $753,120 | 0 |
| PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH FOLFIRI AFTER PROGRESSION ON FOLFIRI PLUS BEVACIZUMAB IN KRAS AND NRAS WILD TYPE METASTATIC COLORECTAL CANCER | Amgen Inc. | $504,832 | 0 |
| Machine learning analysis to identify factors that predict treatment response in patients with metastatic colorectal cancer | Amgen Inc. | $245,000 | 0 |
| Evaluating the efficacy of AMG 510 alone and in combination with chemotherapy in KRAS p.G12C colorectal cancer PDX models | Amgen Inc. | $187,500 | 0 |
| A Randomized, Multicenter Phase II Study of Panitumumab plus FOLFIRI with or without Hepatic Arterial Infusion as Second-line Treatment in Patients with Wild Type RAS who have Unresectable Hepatic Metastases from Colorectal Cancer | Amgen Inc. | $186,223 | 0 |
| Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Cancer | Amgen Inc. | $169,264 | 0 |
| Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy +/- Panitumumab in Potentially Operable Locally Advanced NSCLC | Amgen Inc. | $167,822 | 0 |
| Enhancing Immunotherapy by Targeting the EGFR Pathway in Inflammatory Breast Cancer | Amgen Inc. | $138,144 | 0 |
| Randomized Phase II Trial of Panitumumab, Erlotinib, and Gemcitabine vs. Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma | Amgen Inc. | $92,590 | 0 |
| A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition with Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients with mCRC | Amgen Inc. | $86,193 | 0 |
Top Doctors Receiving Payments for Vectibix
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Mineola, NY | $40.8M | 214 |
| , MD | Medical Oncology | Philadelphia, PA | $223,749 | 294 |
| , M.D | Medical Oncology | Jacksonville, FL | $166,652 | 155 |
| , M.D | Internal Medicine | Las Vegas, NV | $142,731 | 184 |
| , M.D | Medical Oncology | Ocala, FL | $113,968 | 217 |
| , M.D | Internal Medicine | San Antonio, TX | $113,422 | 124 |
| , M.D | Hematology | Santa Rosa, CA | $106,114 | 127 |
| , MD | Hematology | Stamford, CT | $96,973 | 130 |
| , M.D., PH.D | Medical Oncology | Gilbert, AZ | $89,318 | 131 |
| , M.D | Hematology & Oncology | Beverly Hills, CA | $85,850 | 133 |
| , MD | Hematology & Oncology | Orlando, FL | $82,529 | 122 |
| , MD | Internal Medicine | Lake Success, NY | $74,243 | 73 |
| , M.D | Hematology & Oncology | Elk Grove Village, IL | $73,695 | 105 |
| John Marshall | Hematology & Oncology | Washington, DC | $64,834 | 74 |
| , MD | Internal Medicine | Duarte, CA | $63,752 | 44 |
| , M.D | Hematology & Oncology | Miami, FL | $56,243 | 75 |
| , MD | Hematology & Oncology | Indianapolis, IN | $46,347 | 50 |
| , M.D | Internal Medicine | Columbus, OH | $44,514 | 56 |
| , M.D,PH.D | Student in an Organized Health Care Education/Training Program | Goodyear, AZ | $40,850 | 45 |
| , M.D | Medical Oncology | Nashville, TN | $40,285 | 46 |
| , MD | Dermatology | New York, NY | $38,387 | 12 |
| , MD | Internal Medicine | Stony Brook, NY | $35,711 | 43 |
| , MD | Specialist | Norfolk, VA | $35,054 | 51 |
| , MD | Hematology & Oncology | Harvey, IL | $33,341 | 37 |
| , MD | Hematology & Oncology | Glendale, AZ | $26,854 | 34 |
Ad
Manufacturing Companies
- Amgen Inc. $43.1M
Product Information
- Type Biological
- Total Payments $43.1M
- Total Doctors 1,776
- Transactions 5,465
About Vectibix
Vectibix is a biological associated with $43.1M in payments to 1,776 healthcare providers, recorded across 5,465 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2017 to 2024. In 2024, $111,788 was paid across 64 transactions to 36 doctors.
The most common payment nature for Vectibix is "Unspecified" ($40.8M, 94.5% of total).
Vectibix is associated with 20 research studies, including "AMG 510 Ph1b Master Protocol 20190135" ($13.2M).